Findings

What do systematic reviews say?

4,749 questions · 14,273 findings · 834 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,655 · 25.6%GRADE not reported 2,115 · 14.8%Very low 3,646 · 25.5%Low 3,034 · 21.3%Moderate 1,503 · 10.5%High 320 · 2.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Intervention not reported

BEV+VB111 (1 RCT, 128 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention leads to higher BEV+VB111 (1 RCT, 128 participants) (high certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 3.77 [2.25, 6.33]
1 study · 111 participants
High

Intervention not reported

BEV+TRC 105 (1 RCT, 49 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention leads to higher BEV+TRC 105 (1 RCT, 49 participants) (high certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 6.86 [2.55, 18.41]
1 study · 105 participants
High

Intervention not reported

All intervention options · people with first recurrence of glioblastoma Interventions: bevacizumab (BEV), BEV + lomustine (LOM), regorafenib (REG), BEV + irinotecan…

The review found no eligible studies for this question.

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Outcomes (5 RCTs, 1024 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1024 participants
GRADE not reported

Intervention not reported

BEV(8 RCTs; 498 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 498 participants
GRADE not reported

Intervention not reported

FOM (1 RCT, 32 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in FOM (1 RCT, 32 participants); GRADE not reported.

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 0.44 [0.11, 1.72]
1 study · 32 participants
GRADE not reported

Intervention not reported

BEV+HSPPC96 1 RCTs; 53 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in BEV+HSPPC96 1 RCTs; 53 participants) (low certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 1.01 [0.33, 3.1]
1 study · 96 participants
Low

Intervention not reported

BEV+ONA(1 RCT; 64 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in BEV+ONA(1 RCT; 64 participants) (low certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 1.17 [0.57, 2.39]
1 study · 64 participants
Low

Intervention not reported

BEV+CAB (1 RCT; 58 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in BEV+CAB (1 RCT; 58 participants) (low certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 1.27 [0.61, 2.66]
1 study · 58 participants
Low

Intervention not reported

BEV+DAS (2 RCTs, 83 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…

The intervention showed no clear difference in BEV+DAS (2 RCTs, 83 participants) (high certainty).

1 finding from 1 review

Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
RR 0.52 [0.69, 3.34]
2 studies · 83 participants
High

Intervention not reported

studies 1847 participants · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…

1 finding from 1 review

Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network… 2021 · Cochrane Headline outcomes only
no estimate extracted
19 studies · 1847 participants
GRADE not reported

Intervention not reported

CRFWVT (Rezūm) (indirect estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…

1 finding from 1 review

Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Intervention not reported

TUMT (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…

1 finding from 1 review

Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Intervention not reported

TIND (indirect estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…

1 finding from 1 review

Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Intervention not reported

TUMT (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…

The review found no eligible studies for this question.

1 finding from 1 review

Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

TIND (indirect estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…

The review found no eligible studies for this question.

1 finding from 1 review

Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

PAE (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments…

The review found no eligible studies for this question.

1 finding from 1 review

Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

studies 799 participants · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments.…

1 finding from 1 review

Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network… 2021 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 799 participants
GRADE not reported

Intervention not reported

PUL (UroLift) (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments.…

It is very uncertain whether the intervention changes PUL (UroLift) (mixed estimate) (very low certainty).

1 finding from 1 review

Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network… 2021 · Cochrane Headline outcomes only
RR 2.39 [0.51, 11.1]
Studies not reported
Very low

Intervention not reported

PAE (mixed estimate) · men with moderate to severe lower urinary symptoms due to benign prostatic hyperplasia Interventions: minimally invasive treatments.…

It is very uncertain whether the intervention changes PAE (mixed estimate) (very low certainty).

1 finding from 1 review

Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network… 2021 · Cochrane Headline outcomes only
RR 4.39 [1.25, 15.44]
Studies not reported
Very low